Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03511157 · ClinicalTrials.gov registry record · NA
Ischemic Preconditioning Claudication Study
A NA study of Peripheral Arterial Disease and Peripheral Vascular Disease, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03511157: Completed NA study of Peripheral Arterial Disease and Peripheral Vascular Disease, sponsored by Medical College of Wisconsin.
NCT03511157 is a NA study of Peripheral Arterial Disease and Peripheral Vascular Disease that has completed, run by Medical College of Wisconsin. The registered enrollment target is 24 participants, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03511157, a NA study of Peripheral Arterial Disease and Peripheral Vascular Disease, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This study proposes ischemic preconditioning (IPC) as a novel intervention to improve walking distance in patients with intermittent claudication.
Primary Outcome
Subjects will be placed on a motorized treadmill and peak walking time will be recorded in seconds.
Conditions Studied
Interventions
- OTHER Control Group
- OTHER Ischemic Preconditioning
Study Locations (1)
Wisconsin
- Froedtert and the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-06-14 |
| Est. Completion | 2022-12-13 |
| Phase | NA |
What the finished NCT03511157 record still lists
NCT03511157 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 2 interventions - of which Control Group is the first listed.
NCT03511157 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03511157 about?
NCT03511157 is a clinical study titled "Ischemic Preconditioning Claudication Study". This study proposes ischemic preconditioning (IPC) as a novel intervention to improve walking distance in patients with intermittent claudication.
What is the current status of trial NCT03511157?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2018-06-14. Estimated completion is 2022-12-13.
What conditions does trial NCT03511157 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease, Peripheral Vascular Disease, Intermittent Claudication, Ischemia Vascular.
What interventions are being tested in trial NCT03511157?
The interventions under investigation include: Control Group (OTHER), Ischemic Preconditioning (OTHER).
Who is sponsoring clinical trial NCT03511157?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03511157 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03511157's enrollment target sits among peer trials
24 62nd of 79 higher than 17 of 79 other Peripheral Arterial Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease
RECRUITING · NA
-
Prehabilitation and Rehabilitation in PAD
RECRUITING · NA
-
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
RECRUITING · NA
-
Assessment of the Utility of the Pantheris Small Vessel (SV) System
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI